Hussman Strategic Advisors Inc. owned approximately 0.07% of Harmony Biosciences worth $1,158,000 as of its most recent filing with the Securities & Exchange Commission. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $40.87. On average, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year. Also, CFO Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock in a transaction that occurred on Thursday, January 15th. Harmony Biosciences Company Profile(Free Report)Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases.